首页> 外文会议>Nommensen International Conference on Technology and Engineering >Lethality concentration 50 (LC50) assay of Phaleria macrocarpa (Scheff. ) boerl extract in fibroblast cell culture
【24h】

Lethality concentration 50 (LC50) assay of Phaleria macrocarpa (Scheff. ) boerl extract in fibroblast cell culture

机译:偶尔麦克风培养蛋白酶宏观疟疾(Scheff.)偶联50(LC50)测定法分析细胞培养物中的Boerl提取物

获取原文

摘要

Preeclampsia is a major cause in both maternal and perinatal mortality and morbidity. The etiopathogenesis of preeclampsia is still not fully elucidated but it is believed to be a multifactor.it is assumed that preeclampsia is caused by oxidative stress in placenta which cause endothelial and vascular dysfunction.in vitro model research is considered the best and most effective way to understand the disease pathophysiology. Phaleria macrocarpa (Scheff. ) Boerl also known as Mahkota Dewa is widely used as an antioxidant because of alkaloids, saponins, flavonoids and polyphenols properties. The phenol and flavonoid compounds have antioxidant and anti-inflammatory activity. This study aimed to determine Phaleria macrocarpa extract's LC50 in fibroblast cell primary culture. The LC50 was measured based on Brine Shrimp Lethality Test (BSLT) method. The LC50 of Ethyl Acetate fraction of Phaleria macrocarpa extract was 38.16 ppm and the LC50 of N-Hexane Fraction of Phaleria macrocarpa extract was 157. 91 ppm, both measured at 550 nm wavelength. Phaleria macrocarpa extract's LC50 obtained later can be used as reference in subsequent research using trophoblast cell and HUVEC cultures. Further studies regarding the optimal dose of Phaleria macrocarpa extract for clinical trial are encouraged.
机译:预口局部是母亲和围产期死亡率和发病率的主要原因。预坦克西亚的病因发生仍然没有完全阐明,但据信是多重吸引力。假设预坦克敏是由胎盘氧化应激引起的,导致内皮和血管功能障碍。体外模型研究被认为是最佳和最有效的方法了解疾病病理生理学。 Phaleria Macrocarpa(Scheff。)Boerl又称Mahkota Dewa被广泛用作抗氧化剂,因为生物碱,皂苷,黄酮和多酚性质。苯酚和黄酮化合物具有抗氧化剂和抗炎活性。本研究旨在确定偶发蛋白酶宏观疗法的成纤维细胞初级培养物的LC50。基于盐水虾致死性试验(BSLT)方法测量LC50。磷酸乙酸乙酸乙酸乙酯馏分的LC50为38.16ppm,偶丙粥的正己烷级数LC50为157.91ppm,两者在550nm波长下测量。较典礼获得的Phaleria Macrocarpa提取物的LC50可用作使用滋养细胞和Huvec培养物的后续研究中的参考。鼓励关于临床试验最佳剂量的临床试验的最佳剂量的进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号